eCTD Submission Strategies: In-house vs. Outsourcing

Webinar: eCTD Submission Different Strategies: In-house vs. Outsourcing

eCTD Submission Strategies, including outsourcing, are influenced by varying requirements in various regions and countries. That and diverse technical resources by companies often lead to various regulatory strategies. Thus, the questions arises: how to choose the best tactics for eCTD submission that your needs?

The purpose of this webinar is to discuss the different approaches to prepare eCTD submissions, its requirements, technical resources, and process validation.

 

You will learn about:

1. Requirements for eCTD

  • Different forms of eCTD used in EU vs. EAEU eCTD
  • Legislation framework
  • Regions and countries following the eCTD

2. Different approaches to prepare eCTD submissions: In-house vs. Outsourcing

3. Technical resources

  • Software and networks
  • Document and project management
  • Potential challenges

4. How to validate submission to achieve compliance and high quality

  • Tips and tricks

 

Registering a new product?

Make use of our experts to enter new markets. Explore your options in an informal chat with one of our experts.

Who Should Attend? Professionals from the following fields:

  • Regulatory Managers
  • Regulatory Strategy Managers
  • RA Partnerships Operations Manager
  • QA Managers supporting RA
  • RA Healthcare Compliance Managers

 

Duration: 25 min.

Speaker: Head of Global Regulatory Affairs, Olga Bernardova, MSc, who will share her expertise regarding eCTD submissions.

Olga Bernardova, MSc

Olga Bernardova, MSc

Head of Global Regulatory Affairs

Other content that might interest you:

Building Health Literacy: The Value of Good Writing

Building Health Literacy: The Value of Good Writing

Scientists, doctors, and health authorities often use written communication to present their research, opinions, or guidelines to the patients. While the questions they approach may be complex, the language should not. In medical documents, misinterpreted information may endanger the health and life of a patient. Thus, the main goal in medical writing is to convey the message clearly and concisely to avoid misinterpretation.

read more
CMC: Down the road in effective IND/IMPD writing

CMC: Down the road in effective IND/IMPD writing

In the previous two articles, we have shared our experience on various aspects of effective IND/IMPD CMC writing, considering proper planning, assigning a dedicated CMC writing team, and having effective project management. In addition, we discussed technical writing particulars giving some key messages on document preparation. Now, we will discuss other important points. These are safety, data completeness, and geographical regions.

read more
Running a Clinical Trial in Ukraine

Running a Clinical Trial in Ukraine

Despite the fact that Ukraine is the largest country in Eastern Europe with a large population of treatment-naïve patients, well organized public health care sector and significant number of medical sites accredited for clinical trial conduction, country has utilized only 15% of its current potential for hosting clinical trials. During 2017, the European Medicine Agency (EMA) gave positive recommendations on 94 new drug applications and 49 of them were tested in clinical trials in Ukraine. During the same year, the US FDA approved 151 new drugs, and 28 of them were also studied in Ukraine.

read more

Big Enough To Cover  All Your Needs. Small Enough To Care.

Discover the tailored solutions that Biomapas provides to accelerate your clinical trials and optimize your drug development process.

Clinical Research

Regulatory Affairs

Pharmacovigilance

Medical Information